Role of interleukin-23 as a biomarker in rheumatoid arthritis patients and its correlation with disease activity
- 1 February 2016
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 31, 105-108
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory DiseasesInflammation & Allergy - Drug Targets, 2012
- Rheumatoid arthritisThe Lancet, 2010
- IL‐23 in the Pathogenesis of Rheumatoid ArthritisScandinavian Journal of Immunology, 2010
- Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destructionJournal of Experimental Medicine, 2006
- Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two‐year prospective study (the DAMAGE study cohort)Arthritis & Rheumatism, 2006
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationJournal of Experimental Medicine, 2005
- The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal modelsArthritis Research & Therapy, 2005
- Interleukin 17 synergises with tumour necrosis factor α to induce cartilage destruction in vitroAnnals of the Rheumatic Diseases, 2002
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995